Nicotine alone and in combination with L-DOPA methyl ester or the D2 agonist N-0923 in MPTP-induced chronic hemiparkinsonian monkeys

Experimental Neurology

Volumn 158, Issue 2, 1999, Pages 414-421

  Domino, Edward F ^a   Ni, Lisong ^a   Zhang, Huilei ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Dopamine; Dopamine D2 receptor agonist; Hemiparkinsonism; L DOPA methyl ester; Levodopa; Monkeys; MPTP; Nicotine

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVODOPA METHYL ESTER; NICOTINE; ROTIGOTINE; SODIUM CHLORIDE;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARM MOVEMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG POTENTIATION; MONKEY; MOTOR ACTIVITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL;

EID: 0032816456     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1999.7106     Document Type: Article

References (53)

1. Andersson K., Fuxe K., Agnati L. F., Eneroth P. Effects of acute central and peripheral administration of nicotine on ascending dopamine pathways in the male rat brain: Evidence for nicotine induced increase of dopamine turnover in various telencephalic dopamine nerve terminal system. Med. Biol. 59:1981;170-176.
2. Asin K. E., Domino E. F., Nikkel A., Shiosaki K. The selective dopamine D1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and primate models of Parkinson's disease. J. Pharmacol. Exp. Ther. 281:1997;454-459.
3. Bankiewicz K. S., Oldfield E. H., Chiueh C. C., Doppman J. L., Jacobowitz D. M., Kopin I. J. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 39:1986;7-16.
4. Baron J. A. Cigarette smoking and Parkinson's disease. Neurol. 36:1986;1490-1496.
5. Baumann R. J., Jameson H. D., McKean H. E., Haack D. G., Weisberg L. M. Cigarette smoking and Parkinson's disease. I. Comparison of cases with matched neighbors. Neurology. 30:1980;839-843.
6. 2 receptor agonist is efficacious in rat and monkey models of Parkinson's disease. Move. Dis. 9:1994;147-154.
7. Berlin I., Said S., Spreaux-Varoquaux O., Olivares R., Launay J.-M., Puech A. J. Monoamine oxidase A and B activities in heavy smokers. Biol. Psychiatr. 38:1995;756-761.
8. Boulton A. A., Yu P. H., Tipton K. F. Biogenic amine adducts, monoamine oxidase inhibitors and smoking. Lancet. 1:1988;114-115.
9. Clarke P. B. S. Electrophysiological actions of nicotine on substantia nigra single units. Br. J. Pharmacol. 85:1985;827-835.
10. Clarke P. B. S., Kumar R. The effects of nicotine on locomotor activity in nontolerant and tolerant rats. Br. J. Pharmacol. 78:1983;329-337.
11. 3H]-dopamine release. Br. J. Pharmacol. 117:1996;595-606.
12. 11C]tetrabenazine. Synapse. 14:1993;131.
13. DeBelleroche J., Bradford H. F. Biochemical evidence for the presence of presynaptic receptors on dopamine nerve terminals. Brain Res. 142:1978;53-68.
14. 2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys. J. Pharmacol. Exp. Ther. 284:1998;307-311.
15. Domino E. F., Ni L., Zhang H., Kohno Y., Sasa M. Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys. Eur. J. Pharmacol. 325:1997;137-144.
16. Domino E. F., Ni L., Zhang H., Kohno Y., Sasa M. Effects of talipexole on contraversive rotation and functional impairment in MPTP-induced chronic hemiparkinsonian monkeys. Jpn. J. Pharmacol. 77:1998;227-233.
17. 2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine induced hemiparkinsonian monkeys. J. Pharmacol. Exp. Ther. 264:1993;221-225.
18. 2 receptors in MPTP induced hemiparkinsonian monkeys. J. Pharmacol. Exp. Ther. 265:1993;1387-1391.
19. Fagerström K. O., Pomerleau O., Giordani B., Stelson F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology. 116:1994;117-119.
20. Fowler J. S., Volkow N. D., Wang G.-J., Pappas N., Logan J., MacGregor R., Alexoff D., Shea C., Schyler D., Wolf A. P., Warner D., Zezulkova I., Cilento R. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 379:1996;733-736.
21. Godwin-Austen R. B., Lee P. N., Marmot M. G., Stern G. M. Smoking and Parkinson's disease. J. Neurol. Neurosurg. Psychiat. 45:1982;577-581.
22. 3H]dopamine release from synaptosomes prepared from mouse striatum. Neurochemistry. 59:1992;848-856.
23. Hubble J. P., Cao T., Hassanein R. E. S., Neuberger J. S., Koller W. C. Risk factors for Parkinson's disease. Neurology. 43:1993;1693-1697.
24. Ishikawa A., Miyatake T. Effects of smoking in patients with early-onset Parkinson's disease. J. Neurol. Sci. 117:1993;28-32.
25. Jörg J., Schneider I. Zur Klinik und Pathogenese des "on-off"-Phänomens beim Parkinson-Syndrom. Fotschr. Neurol. Psychiat. 56:1988;22-34.
26. Kita T., Okamoto M., Nakashima T. Nicotine-induced sensitization of ambulatory stimulation effects produced by daily administration into the ventral tegmental area and nucleus accumbens in rats. Life Sci. 50:1992;583-590.
27. 3H]acetylcholine to nicotine receptors. Neuropharmacology. 24:1985;527-531.
28. Lichtensteiger W., Felix D., Lienhart R., Hefti F. A quantitative correlation between single unit activity and fluorescence intensity of dopamine neurons in zona compacta ofsubstantia nigra, as demonstrated under the influence of nicotine and physostigmine. Brain Res. 117:1976;85-103.
29. Lichtensteiger W., Hefti F., Felix D., Huwyler T., Melamed E., Schlumpf M. Stimulation of nigrostriatal dopamine neurones by nicotine. Neuropharmacology. 21:1982;963-968.
30. McGehee D. S., Heath M. J. S., Gelber S., Davay P., Role L. W. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science. 269:1995;1692-1696.
31. Mayeux R., Tang M.-X., Marder K., Cote L. J., Stern Y. Smoking and Parkinson's disease. Move. Dis. 92:1994;207-212.
32. Moll H. The treatment of post encephalitic parkinsonism by nicotine. Br. Med. J. 1:1926;1079-1081.
33. Norman T. R., Chamberlain K. G., French M. A. Platelet monoamine oxidase: Low activity in cigarette smokers. Psychiat. Res. 20:1987;199-205.
34. Norman T. R., Chamberlain K. G., French M. A., Burrows G. D. Platelet monoamine oxidase activity and cigarette smoking. J. Affect. Dis. 4:1982;73-77.
35. Oreland L., Fowler C. J., Schalling D. Low platelet monoamine oxidase activity in cigarette smokers. Life Sci. 29:1981;2511-2518.
36. Pope-Coleman A., Lloyd G. K., Schneider J. S. The nicotinic receptor agonist SIB-1508Y potentiates l-DOPA responses in parkinsonian monkeys. Soc. Neurosci. Abstr. 22:1996;217.
37. Schneider J. S., Pope-Coleman A., Van Velson M., Menzaghi F., Lloyd G. K. Effects of S1B-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys. Move. Dis. 13:1998;637-642.
38. Schneider J. S., Sun Z. Q., Roeltgen D. P. Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys. Brain Res. 663:1994;140-144.
39. Schneider J. S., Van Velson M., Menzaghi F., Lloyd G. K. Effects of the nicotinic acetylcholine receptor agonist S1B-1508Y on object retrieval performance in MPTP-treated monkeys: Comparison with levodopa treatment. Ann. Neurol. 43:1998;311-317.
40. Shoaib M., Stolerman I. P. MK-801 attenuates behavioural adaptation to chronic nicotine administration in the rat. Br. J. Pharmacol. 105:1992;514-515.
41. Shoaib M., Stolerman I. P. The NMDA antagonist dizocilpine (MK-801) attenuates tolerance to nicotine in rats. J. Psychopharmacol. 10:1996;214-218.
42. Shoaib M., Benwell M. E. M., Akbar M. T., Stolerman I. P., Balfour D. J. K. Behavioural and neurochemical adaptation to nicotine in the rat: Influence of NMDA antagonists. Br. J. Pharmacol. 111:1994;1073-1080.
43. Smith C. J., Giacobini E. Nicotine, Parkinson's and Alzheimer's disease. Rev. Neurosci. 3:1992;25-42.
44. Stolerman I. P., Shoaib M. The neurobiology of nicotine addiction. Trends Pharmacol. Sci. 12:1991;467-473.
45. Vezina P., Herve D., Glowinski J., Tassin J. P. Injections of 6-hydroxydopamine into the ventral tegmental area destroy mesolimbic dopamine neurons but spare the locomotor activating effects of nicotine in the rat. Neurosci. Lett. 168:1994;106-110.
46. Vincent W. J. Statistics in Kinesiology. 1995;Human Kinetics, Champaign.
47. 3H-dopamine from rat brain slices. Neuropharmacology. 13:1974;693-700.
48. Westfall T. C., Mereu G., Vickery L., Perry H., Naes L., Yoon K.-W. P. Regulation by nicotine of midbrain dopamine neurons. Nordbert A., Fuxe K., Holmstedt B., Sundwall A. Progress in Brain Research. 1989;173-185 Elsevier, Amsterdam.
49. Whiteaker P., Garcha H. S., Wonnacott S., Stolerman I. P. Locomotor activation and dopamine release produced by nicotine and isoarecolone in rats. Br. J. Pharmacol. 116:1995;2097-2105.
50. Wise R. A., Bozarth M. A. A psychomotor stimulant theory of addiction. Psychol. Rev. 94:1987;469-492.
51. Wise R. A., Rompre P.-P. Brain dopamine and reward. Annu. Rev. Psychol. 40:1989;191-225.
52. Wonnacott S. Presynaptic nicotinic ACh receptor. Trends Neurosci. 20:1997;92-98.
53. Yu P. H., Boulton A. A. Irreversible inhibition of MAO by some components of cigarette smoke. Life Sci. 41:1987;675-682.